Active, not recruitingPhase 2NCT05679570

Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)

Studying Idiopathic pulmonary arterial hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
International University of Health and Welfare
Principal Investigator
Yuichi Tamura
International University of Health and Welfare
Intervention
Satralizumab (Genetical Recombination)(drug)
Enrollment
20 enrolled
Eligibility
20-79 years · All sexes
Timeline
20222026

Study locations (9)

Collaborators

Japan Agency for Medical Research and Development · Keio University · Chugai Pharmaceutical

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05679570 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary arterial hypertension

← Back to all trials